search
contrast therapy
Trends
- 1SLS Stock Falls on AML Trial Milestone Despite Bullish Retail Bets▼SLS Stock’s Big AML Trial Milestone Sparks A Selloff — What’s Fueling Retail’s ‘Extremely Bullish’ Bets?
Shares of SLS sold off after the company reached a significant milestone in its acute myeloid leukemia (AML) trial, an outcome investors might normally welcome. Retail traders, however, are described as 'extremely bullish' on the stock, buying the dip and betting on the therapy's prospects. The split between an institutional selloff and enthusiastic retail accumulation is drawing attention across trading forums and finance outlets.
- 2Rehabilitation robot passes hospital test but unsettles physiotherapists▼Robot rehabilitation platform works flawlessly but flusters physiotherapists in first hospital test
A robot-assisted rehabilitation platform has been trialled for the first time in a hospital setting, where it reportedly performed flawlessly. The technology's smooth technical debut nonetheless left physiotherapists feeling flustered, highlighting the human tensions that can accompany automation in clinical work. The trial raises questions about training, workflow integration and how therapy staff adapt to robotic systems.
- 3NRG1 fusions and HER2 overexpression: same pathway, distinct biology▼NRG1 fusion vs HER2 overexpression: A shared pathway but distinct biology
Oncology discussions are contrasting NRG1 gene fusions with HER2 overexpression, two cancer drivers that activate the same ErbB signaling pathway but behave as biologically distinct entities. The comparison highlights that despite shared downstream signaling, the two alterations differ in their underlying biology, which has implications for how tumors are classified and how targeted therapies are selected for patients carrying each alteration.